Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by AKAMPION

< Previous 1 2 Next >
BellaSeno Successfully Completes Two Clinical Trials with Novel, Resorbable Breast Implants
From AKAMPION
Via GlobeNewswire
tiakis Biotech AG Receives Positive Scientific Advice from the U.S. FDA for Planned Phase II Trial of Tiprelestat
From AKAMPION
Via GlobeNewswire
Next-generation RNA company Inverna Therapeutics launched by Argobio and University of Southern Denmark
From AKAMPION
Via GlobeNewswire
tiakis Biotech AG Reports Clinical Phase Ib/II Trial Results of Tiprelestat for the Treatment of Hospitalized COVID-19 Patients
From AKAMPION
Via GlobeNewswire
Thermosome Initiates Final Dose Level in Phase I Trial of Lead Compound THE001
From AKAMPION
Via GlobeNewswire
Thermosome Presents Encouraging Initial Clinical Data from Phase I Trial of Lead Compound THE001
From AKAMPION
Via GlobeNewswire
Ebenbuild Appoints Charles A. Taylor, PhD as Chairman of the Board
From AKAMPION
Via GlobeNewswire
AMYRA Successfully Demonstrates a New Therapeutic Paradigm for Gluten-Related Disorders in a First-in-Human Study
From AKAMPION
Via GlobeNewswire
Preliminary Data of BellaSeno’s Clinical Trial on Scaffold-Guided Breast Regeneration Presented at the 93rd Annual Plastic Surgery Meeting in San Diego, CA
From AKAMPION
Via GlobeNewswire
Mabylon AG Receives Research Grants Totaling More Than CHF 1.3 Million for Amyotrophic Lateral Sclerosis (ALS) and Inflammasome Programs
From AKAMPION
Via GlobeNewswire
ImmunOs Therapeutics AG Raises $11 Million and Further Strengthens Investor Base
From AKAMPION
Via GlobeNewswire
ImmunOs Therapeutics Expands Phase I Clinical Trial of IOS-1002 in Combination with KEYTRUDA® (pembrolizumab) for the Treatment of Solid Tumors
From AKAMPION
Via GlobeNewswire
BellaSeno Reports Positive Interim Findings of Australian Clinical Trials in Breast Scaffold Patients
From AKAMPION
Via GlobeNewswire
Thermosome Appoints Dr. Sabine Hauck as Chief Technical Officer
From AKAMPION
Via GlobeNewswire
BellaSeno Receives Financial Support Through Queensland’s Industry Partnership Program
From AKAMPION
Via GlobeNewswire
selectION Announces Initiation of Phase 1b Clinical Trial Evaluating si-544 in Patients with Psoriasis Vulgaris or Psoriatic Arthritis
From AKAMPION
Via GlobeNewswire
Captain T Cell Secures Seed Financing Round Totaling € 8.5 Million
From AKAMPION
Via GlobeNewswire
Atopia Therapeutics, Formerly HpVac, Announces Appointment of Dr. Gregoire Chevalier as CEO and Business Update
From AKAMPION
Via GlobeNewswire
selectION Announces Positive Results from Phase 1b Clinical Trial Evaluating si-544 in Patients with Atopic Dermatitis
From AKAMPION
Via GlobeNewswire
Transferring Biomedical Research to Patients Faster: ForTra gGmbH Announces Positive Funding Track Record
From AKAMPION
Via GlobeNewswire
BellaSeno Appoints Dr. Thomas Lingner as Chief Technology Officer and Inga Freyert as VP Quality and Regulatory Affairs
From AKAMPION
Via GlobeNewswire
MetrioPharm Establishes Scientific Advisory Board of Seasoned Immunology and Pediatric Experts
From AKAMPION
Via GlobeNewswire
BellaSeno’s 3D-printed Resorbable Scaffold Successfully Used in Critical-Size Large Segmental Radius Bone Defect at Hannover Medical School
From AKAMPION
Via GlobeNewswire
Omnix Medical Granted Fast-Track Designation by U.S. FDA for its Next-Generation Anti-Infective OMN6
From AKAMPION
Via GlobeNewswire
Thermosome Announces Further Dose Escalation in Phase I Trial with Lead Program THE001
From AKAMPION
Via GlobeNewswire
MetrioPharm Publishes First Trial Data Showing Effects of Host-Directed Therapy in COVID-19
From AKAMPION
Via GlobeNewswire
New investigator-initiated clinical trials of BellaSeno´s resorbable tissue regeneration scaffolds to be conducted in Europe
From AKAMPION
Via GlobeNewswire
selectION, Inc. to Present Update on Clinical Progress at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on January 11, 2024
From AKAMPION
Via GlobeNewswire
1ST Biotherapeutics, Inc. Announces First Patient Dosed in Phase I/II Study of HPK1 Inhibitor FB849 in Patients with Advanced Solid Tumors
From AKAMPION
Via GlobeNewswire
ImmunOs Therapeutics Presents Details of Novel Bispecific Anti-Tumor Molecules at ESMO Immuno-Oncology Congress 2023
From AKAMPION
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.